Flt3 Receptor Tyrosine Kinase as a Drug Target in Leukemia

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|10|16|1867-1883

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.10, Iss.16, 2004-06, pp. : 1867-1883

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3–tyrosine kinase domain mutations

By Alvarado Yesid   Kantarjian Hagop M.   Luthra Rajyalakshmi   Ravandi Farhad   Borthakur Gautam   Garcia-Manero Guillermo   Konopleva Marina   Estrov Zeev   Andreeff Michael   Cortes Jorge E.  

Cancer, Vol. 120, Iss. 14, 2014-07 ,pp. : 2142-2149

Blackwell Publishing

Access to resources Recommend Favorite

Novel FLT3 tyrosine kinase inhibitors

By Levis Mark   Small Donald  

Expert Opinion on Investigational Drugs, Vol. 12, Iss. 12, 2003-12 ,pp. : 1951-1962

Informa Healthcare

Access to resources Recommend Favorite

Small Molecule FLT3 Tyrosine Kinase Inhibitors

By  

Current Pharmaceutical Design, Vol. 10, Iss. 11, 2004-04 ,pp. : 1183-1193

Bentham Science Publishers

Access to resources Recommend Favorite

Abnormal Localization and Accumulation of FLT3-ITD, a Mutant Receptor Tyrosine Kinase Involved in Leukemogenesis

By  

Cells Tissues Organs, Vol. 188, Iss. 1-2, 2008-02 ,pp. : 225-235

Karger

Access to resources Recommend Favorite

FLT3 as a Therapeutic Target in Childhood Acute Leukemia

By  

Current Drug Targets, Vol. 8, Iss. 6, 2007-06 ,pp. : 703-714

Bentham Science Publishers

Access to resources Recommend Favorite